Cambridge, MA-based Metamark Genetics said today it had entered into a research agreement with Janssen Biotech, a unit of New Brunswick, NJ-based Johnson & Johnson (NYSE: [[ticker:JNJ]]). Metamark, which was founded in 2007 on science from the Dana-Farber Cancer Institute, is developing prognostic tests based on genes discovered to play a role in how tumors progress and spread.
Metamark and Janssen will work together to validate some of those gene targets. Once targets are chosen for further pursuit, Janssen will be responsible for the development and commercialization of therapies meant to inhibit those genes.
Under the agreement, Metamark will receive an undisclosed up-front payment and will be eligible for up to $365 million in milestone payments.
.
Author: Arlene Weintraub
Arlene is an award-winning journalist specializing in life sciences and technology. She was previously a senior health writer based out of the New York City headquarters of BusinessWeek, where she wrote hundreds of articles that explored both the science and business of health. Her freelance pieces have been published in USA Today, US News & World Report, Technology Review, and other media outlets. Arlene has won awards from the New York Press Club, the Association of Health Care Journalists, the Foundation for Biomedical Research, and the American Society of Business Publication Editors. Her book about the anti-aging industry, Selling the Fountain of Youth, was published by Basic Books in September 2010.
View all posts by Arlene Weintraub
